In order to commercialize high-tech biopharmaceuticals, which are evaluated as ultra-high-priced new drugs, it has been argued that a policy to recognize insurance benefits should follow beyond Expedited Review within at least a year of approval.

It is pointed out that although the enactment of the Advanced Regenerative Bio Act in 2019 established a quick marketing permit system for serious and rare diseases without alternative treatments, there is still no system to register benefit.

Professor Kim Won-seok of the Department of Blood Tumor Medicine at Samsung Medical Center will present the presentation at the National Assembly's debate on how to improve accessibility of patients with adv